Abstract
Schwannomatosis is the third major form of neurofibromatosis (NF) and is distinct from NF1 and NF2. The disease is not well recognized in Asian countries and the role of germline SMARCB1 mutations requires investigation. A 35-year-old Japanese man complaining of headache underwent an MRI examination, which showed a cystic tumor at the left cerebellopontine angle. The tumor was surgically removed and diagnosed as vagus nerve schwannoma. He had a past medical history of multiple schwannomas of the neck, groin and intercostal nerves, which were also treated surgically. He had a family history of multiple schwannomas for his father and sister. Systemic examinations of these family members ruled out a diagnosis of NF1 or NF2, and thus schwannomatosis was suspected. Genetic analysis revealed a germline mutation (c. *82C > T) of SMARCB1, and a somatic mutation of NF2 without loss of heterozygosity at the chromosome 22 locus. This is the first report of familial schwannomatosis associated with a germline mutation of SMARCB1 in an Asian country.
This is a preview of subscription content, log in via an institution to check access.
References
Boyd C, Smith MJ, Kluwe L et al (2008) Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis. Clin Genet 74:358–366
Gonzalvo A, Fowler A, Cook RJ et al (2011) Schwannomatosis, sporadic schwannomatosis, and familial schwannomatosis: a surgical series with long-term follow-up. Clinical article. J Neurosurg 114:756–762
Hadfield KD, Newman WG, Bowers NL et al (2008) Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis. J Med Genet 45:332–339
Hulsebos TJ, Plomp AS, Wolterman RA et al (2007) Germline mutation of INI1/SMARCB1 in familial schwannomatosis. Am J Hum Genet 80:805–810
Maccollin M, Woodfin W, Kronn D et al (1996) Schwannomatosis: a clinical and pathologic study. Neurology 46:1072–1079
Merker VL, Esparza S, Smith MJ et al (2012) Clinical features of schwannomatosis: a retrospective analysis of 87 patients. Oncologist 17:1317–1322
Murakami Y, Wataya-Kaneda M, Tanaka M et al (2009) Case of schwannomatosis. J Dermatol 36:508–511
Nakajima J, Eminoglu TF, Vatansever G et al (2014) A novel homozygous YARS2 mutation causes severe myopathy, lactic acidosis, and sideroblastic anemia 2. J Hum Genet 59:229–232
Patil S, Perry A, Maccollin M et al (2008) Immunohistochemical analysis supports a role for INI1/SMARCB1 in hereditary forms of schwannomas, but not in solitary, sporadic schwannomas. Brain Pathol 18:517–519
Piotrowski A, Xie J, Liu YF et al (2014) Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas. Nat Genet 46:182–187
Plotkin SR, Blakeley JO, Evans DG et al (2013) Update from the 2011 international schwannomatosis workshop: from genetics to diagnostic criteria. Am J Med Genet A 161:405–416
Sestini R, Bacci C, Provenzano A et al (2008) Evidence of a four-hit mechanism involving SMARCB1 and NF2 in schwannomatosis-associated schwannomas. Hum Mutat 29:227–231
Shishiba T, Niimura M, Ohtsuka F et al (1984) Multiple cutaneous neurilemmomas as a skin manifestation of neurilemmomatosis. J Am Acad Dermatol 10:744–754
Smith MJ, Wallace AJ, Bowers NL et al (2012) Frequency of SMARCB1 mutations in familial and sporadic schwannomatosis. Neurogenetics 13:141–145
Yukizane H, Harimaya K, Doi T (2009) Clinical characteristics of spinal schwannomatosis. Orthop Traumatol 58:406–410
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Asai, K., Tani, S., Mineharu, Y. et al. Familial schwannomatosis with a germline mutation of SMARCB1 in Japan. Brain Tumor Pathol 32, 216–220 (2015). https://doi.org/10.1007/s10014-015-0213-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10014-015-0213-9